scPharmaceuticals rises after MannKind's buyout deal

MannKind

25/08/2025 14:53

Updates

** Shares of drugmaker scPharmaceuticals SCPH.O rise 13% to $5.48

** Biotech firm MannKind Corp's MNKD.O to buy scPharmaceuticals in a deal valued up to $360 million, companies say

** MNKD's shares fall 5.3% to $3.89

** Under the deal, MNKD will pay $5.35 per share upfront in cash, plus offer a non-tradable CVR worth up to $1 per share if certain regulatory and sales milestones are met

** The deal will allow MannKind to expand its portfolio beyond orphan lung diseases

** SCPH brings Furoscix, an FDA-approved on-body infuser to treat adults with chronic heart failure and kidney disease with over $10 billion market opportunity in U.S., according to the companies

** The transaction is expected to close in Q4

** Including session's move, MNKD down 39.8%, while SCPH up 54.9% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))